SEC Form 4 · accession 0001209191-18-050050
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carman Alenson
Officer — Principal Accounting Officer
Period of report
Sep 5, 2018
Accepted (ET)
Sep 7, 2018 · 4:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Sep 5, 2018 | M | 312 | $52.29 | A | 464 | D | |
| Common stock | Sep 5, 2018 | S | 312 | $83.00 | D | 152 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F4 | $52.29 | Sep 5, 2018 | M | 312 | D | — | Nov 6, 2026 | Common stock | 312 | 12,266 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Includes 152 shares purchased through the Company's employee stock purchase plan.
- F3This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F4This option was granted on November 7, 2016. The shares underlying this option vest as to 25% of the underlying shares on November 7, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.